Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report

被引：6

作者：

Michalova, Zuzana ^{[1
,2
,3
]}

Coma, Matus ^{[3
,4
]}

Kicova, Miroslava ^{[1
,2
,3
]}

Gabzdilova, Juliana ^{[5
,6
]}

Dedinska, Kinga ^{[5
,6
]}

Guman, Tomas ^{[5
,6
]}

Hajikova, Martina ^{[1
,2
,3
]}

Veselinyova, Dominika ^{[7
]}

Giertlova, Maria ^{[7
]}

Gal, Peter ^{[4
,8
,9
]}

Sarissky, Marek ^{[1
,2
,3
]}

机构：

[1] Safarik Univ, Fac Med, Dept Pharmacol, Cent Lab Clin Cytometry, Kosice, Slovakia

[2] Medirex As, Kosice, Slovakia

[3] Safarik Univ, Fac Med, Dept Pharmacol, Trieda SNP 1, Kosice, Slovakia

[4] East Slovak Inst Cardiovasc Dis Inc, Dept Biomed Res, Ondayska 8, Kosice 04011, Slovakia

[5] Safarik Univ, Louis Pasteur Univ Hosp, Dept Hematol & Oncohematol, Kosice, Slovakia

[6] Safarik Univ, Fac Med, Kosice, Slovakia

[7] Medirex As, Dept Clin Genet, Kosice, Slovakia

[8] Charles Univ Prague, Fac Med 3, Prague Burn Ctr, Prague, Czech Republic

[9] Safarik Univ, Lab Cell Interact, MediPk, Kosice, Slovakia

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 06期

关键词：

Galectin-3; chronic lymphocytic leukemia; B-cells; flow cytometry; cytogenetics; 17p deletion; B-CELL LYMPHOMA; EXPRESSION; MOLECULES; WORKSHOP;

D O I：

10.21873/anticanres.13408

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Galectins belong to the family of galactose-binding proteins known to play an important role in the processes of cell proliferation, differentiation, migration and neoplastic progression. Herein, we studied the expression of galectin-3 (Gal-3) in chronic lymphocytic leukemia (CLL). Materials and Methods: The expression of Gal-3 was analyzed by means of multiparametric flow cytometry in normal and pathological B-cells from peripheral blood and bone marrow samples of 67 patients with CLL. Results: Pathological B-cells expressed significantly higher levels of cytoplasmic Gal-3 than normal B-cells. Moreover, overexpression of cytoplasmic Gal-3 was observed in the prognostically poorest subgroup of CLL patients, namely those with 17p deletion. Conclusion: Our results indicate a possible role of galectin-3 in CLL pathophysiology and its potential value as a prognostic marker and therapeutic target.

引用

页码：2805 / 2810

页数：6

共 50 条

[1] Chronic lymphocytic leukemia with deletion 17p: An Indian scenario
Gogia, Ajay
Gupta, Ritu
Kumar, Lalit
Sharma, Atul
Soni, Lata
SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (01) : 40 - +
[2] FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DELETION 17P
Strati, P.
Keating, M.
O'Brien, S.
Ferrajoli, A.
Burger, J.
Faderl, S.
Jain, N.
Wierda, W.
HAEMATOLOGICA, 2013, 98 : 45 - 45
[3] Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia
Salem, Ahmed Hamed
Dunbar, Martin
Agarwal, Suresh K.
ANTI-CANCER DRUGS, 2017, 28 (08) : 911 - 914
[4] The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia
Yuan, Ying-Ying
Zhu, Hua-Yuan
Wu, Jia-Zhu
Xia, Yi
Liang, Jin-Hua
Wu, Wei
Cao, Lei
Wang, Li
Fan, Lei
Li, Jian-Yong
Xu, Wei
GENES CHROMOSOMES & CANCER, 2019, 58 (01): : 43 - 51
[5] What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
Sellner, L.
Denzinger, S.
Dietrich, S.
Glimm, H.
Merkel, O.
Dreger, P.
Zenz, T.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 81 - 90
[6] 17p Deletion in Chronic Lymphocytic Leukemia Risk Stratification and Therapeutic Approach
Schnaiter, Andrea
Stilgenbauer, Stephan
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (02) : 289 - +
[7] What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
L. Sellner
S. Denzinger
S. Dietrich
H. Glimm
O. Merkel
P. Dreger
T. Zenz
Current Hematologic Malignancy Reports, 2013, 8 : 81 - 90
[8] 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
Bagacean, Cristina
Tempescul, Adrian
Ternant, David
Banet, Anne
Douet-Guilbert, Nathalie
Bordron, Anne
Bendaoud, Boutahar
Saad, Hussam
Zdrenghea, Mihnea
Berthou, Christian
Paintaud, Gilles
Renaudineau, Yves
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[9] Treatment of patients with chronic lymphocytic leukemia with 17p deletion: the saga continues
Castro, Januario E.
LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 179 - 180
[10] TRANSLOCATION IS A FREQUENT MECHANISM FOR 17P DELETION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Sobotka, J.
Breicha, M.
Brychtova, Y.
Doubek, M.
Holubova, V.
Tovarysova, A.
Stoklasova, M.
Czekajova, A.
Sablaturova, T.
Wrobel, M.
Klodova, D.
Bogoczova, E.
Adamova, D.
Heinzova, V.
Zivna, J.
Plevova, K.
Pospisilova, S.
Mayer, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 40 - 40

← 1 2 3 4 5 →